AXADVOCACY GOVERNMENT RELATIONS

Lobbying for IMMIX BIOPHARMA INC. · Clinical-stage biopharmaceutical company developing next-generation CAR-T cell therapies.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $20,000.00 income · posted Jul 17, 2026

Lobbying activity 1

Health Issues

Issues related to FDA drug approval processes.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.